A Prospective Multicenter Clinical Study of Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors

NCT04892498 Phase 2 UNKNOWN

This is a prospective multicenter clinical study to determine the efficacy and safety of hypofractionated radiotherapy combined with PD-1 inhibitor sequential GM-CSF and IL-2 for advanced multiple metastatic solid tumors

Details

Lead sponsor	Second Affiliated Hospital of Soochow University
Phase	Phase 2
Status	UNKNOWN
Enrolment	66
Start date	2021-05-30
Completion	2024-08

Conditions

• Advanced Refractory Solid Tumors

Interventions

• Hypofractionated radiotherapy
• PD-1 inhibitor
• GM-CSF
• IL-2

Primary outcomes

• progression free survival，PFS — Up to 3 years
  Time from cycle 1, day 1 of treatment to disease progression or death due to any cause

Countries

China